Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA -1.72% Revenue per Share is $0.19 as of Jun. 2026. The stock has 5 warning signs investors should review. Among 767 Biotechnology companies, Emmaus Life Sciences ranks worse than 75.62% on this metric.
Emmaus Life Sciences's revenue per share for the
three
months ended in Jun. 2026 was $0.05.
Emmaus Life Sciences's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.19.
Warning Sign:
Emmaus Life Sciences Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Emmaus Life Sciences was -12.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -19.50% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -14.40% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -12.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Emmaus Life Sciences's Revenue per Share or its related term are showing as below:
EMMA'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -85.2 Med: -20.6 Max: 75.1
Current: -19.5
During the past 13 years, Emmaus Life Sciences's highest 3-Year average Revenue Per Share Growth Rate was 75.10% per year. The lowest was -85.20% per year. And the median was -20.60% per year.
EMMA's 3-Year Revenue Growth Rate is ranked worse than 75.62% of 767
companies
in the Biotechnology industry
Industry Median: 3.1
vs EMMA: -19.50
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Emmaus Life Sciences Revenue per Share Related Terms
Emmaus Life Sciences Revenue per Share Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs PCSA, LIMN, KAPA: Revenue per Share Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's PS Ratio falls into.
Emmaus Life Sciences Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Emmaus Life Sciences's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Revenue per Share of $0.19 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #580 out of 767 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Emmaus Life Sciences' Revenue per Share too high?
Emmaus Life Sciences' current Revenue per Share is $0.19. The Biotechnology industry median Revenue per Share is 3.10. Emmaus Life Sciences' value of $0.19 is 93.9% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #580 out of 767 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Revenue per Share compare to PCSA and LIMN?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #580 out of 767 companies for Revenue per Share. This places Emmaus Life Sciences in the lower half of its industry. The industry median Revenue per Share is 3.10. Emmaus Life Sciences' value of $0.19 is 93.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Revenue per Share of $0.19 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Revenue per Share is $0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.06 — trading 501.5% above its estimated fair value. The current Revenue per Share is $0.19 and 93.9% below the Biotechnology industry median of 3.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Revenue per Share is $0.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
